• Loading stock data...
PublicWire | Emerging Market Stock News
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
No Result
View All Result
PublicWire
No Result
View All Result

Home » Medical » AntriaBio Announces $13 Million Close of Private Placement Transaction and Plan to Dose First Patient with AB101 This Month

AntriaBio Announces $13 Million Close of Private Placement Transaction and Plan to Dose First Patient with AB101 This Month

Anthony Ramsumiran by Anthony Ramsumiran
April 26, 2019
in Medical
3 min read
31
0
AntriaBio Announces $13 Million Close of Private Placement Transaction and Plan to Dose First Patient with AB101 This Month

LOUISVILLE, CO–ANTB, (Marketwired – July 17, 2017) – AntriaBio, Inc. (“AntriaBio or the “Company”) (OTCQB: ANTB), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with diabetes and metabolic diseases, announced today that it has closed on a total of $13 million as part of a planned private placement transaction. Under the terms of the financing, accredited investors paid $1.00 for one share of common stock.

The amount raised to date includes investments made by two South Korean-based pharmaceutical companies, Aju Pharm and Ildong Pharmaceutical Co., Ltd. as well as a South Korean-based investment fund, Medici Investment Co., LTD.

The Company will use the proceeds for general corporate purposes including the Phase 1 clinical study of AB101, an injectable once-weekly basal insulin, as well as emerging pipeline candidates for patients with type 1 and type 2 diabetes. AntriaBio’s recently filed Investigational New Drug (IND) Application for AB101 became effective without hold on July 1. The Company is proceeding with its planned first-in-human clinical trial of AB101 and anticipates dosing of the first patient with AB101 prior to the end of this month.

The securities sold in the financing have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the US absent registration or an applicable exemption from registration requirements.

THIS PRESS RELEASE IS BEING ISSUED PURSUANT TO RULE 135C UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY THE SECURITIES, NOR SHALL THERE BE ANY SALE OF THE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO THE REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF SUCH STATE. ANY OFFERING OF THE SECURITIES UNDER THE RESALE REGISTRATION STATEMENT WILL ONLY BE BY MEANS OF A PROSPECTUS.

About AntriaBio, Inc. 
AntriaBio is a clinical stage biopharmaceutical growth company specializing in the development of innovative drug therapies to improve the lives of patients with diabetes and metabolic diseases. AntriaBio’s lead product candidate is AB101, an injectable once-weekly basal insulin for type 1 and type 2 diabetes that addresses a > $10 billion market where the current standard of care is a once-daily basal insulin injection. For more information visit: www.antriabio.com.

Forward-Looking Statements
This release, like many written and oral communications presented by AntriaBio, Inc., and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, AntriaBio undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.

AntriaBio, Inc. Contact:
Noopur Liffick
VP of Corporate Development
(650) 549-4175

Tags: AntriaBio Incbiopharmaceuticaldiabetesmetabolic diseasesPrivate Placement
Anthony Ramsumiran

Anthony Ramsumiran

Anthony has a very strong background in Economics. He was born and raised in London and is now based in Orlando, Florida. With over 17 years of experience in automotive and technology.

Related Posts

Regeneron buy back shares from Sanofi
Medical

Regeneron to buy back $5 billion shares from Sanofi

May 25, 2020
137
A report reveals that China is deliberately faking the number of COVID-19 cases and deaths.
General

China is underreporting COVID-19 cases, U.S. intelligence community says

April 1, 2020
152
Around the world, the total number of confirmed coronavirus infection went beyond 600,000, with 28,964 fatalities as of the latest report.
Medical

17% of all confirmed COVID-19 cases in the world comes from the US

March 28, 2020
138
President Donald Trump signed a $2 trillion coronavirus relief bill on Friday
General

Trump signs $2 trillion coronavirus relief

March 28, 2020
121
General Motors and Ventec Life Systems are partnering to convert the GM Kokomo, Indiana ERC building for the production of Ventec ventilators in response to the COVID-19 pandemic.
General

GM announces the start of production of critical-care ventilators shortly after Trump’s tweets against CEO

March 27, 2020
134
Rep. Thomas Massie, R-Ky., tried to force a full yes or no vote on the measure, which could have delayed its passage by hours.
Finance

$2 trillion coronavirus stimulus package passed by the House amid efforts to delay voting by Massie

March 27, 2020
122
Currently Playing

Subscribe To Our Newsletter

Ad

PublicWire | Emerging Market Stock News 24/7 | Investor Relations US Stock Market

© Copyright 2020 PublicWire.com

Navigate Site

  • About
  • #96576 (no title)
  • Disclaimer
  • Watch LIVE
  • Privacy Policy
  • Terms and Services
  • Contributors

Follow Us

No Result
View All Result
  • LIVE Investor News Channel
  • Cannabis
  • Energy
  • Finance
  • General
  • Medical
  • Podcasts
  • Retail
  • Technology
  • #370 (no title)

© Copyright 2020 PublicWire.com

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Public Wire Logo

Hello please subscribe to our newsletter to get up to date news weekly!

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.